- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05252806
Quantitative mpMRI to Predict Metastatic Potential of Prostate Cancer (QmpMRI)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Patients diagnosed with prostate cancer will likely not die from the primary tumor, but from (extended) metastatic disease. One of the first steps towards extended metastatic disease is the presence of lymph node metastases, which is an important factor in determining therapy and prognosis. Although historically all patients with lymph node metastases are considered incurable, research has shown that patients with only a limited number of small (<8 mm) nodal metastases have a better prognosis as compared to patients with more extensive involvement. In patients with only a limited number of small nodal metastases (oligo-metastatic), therapy with curative intent might be pursued, e.g. by surgical resection or loco-regional radiotherapy. With continuously improving opportunities to very selectively treat small numbers of metastatic sites it is of utmost importance to accurately diagnose the first signs of oligo-metastatic disease and to define its extent.
It is hypothesized that magnetic resonance imaging (MRI) can obtain more information from the local prostate than what is now used in the clinic to stage localized prostate cancer and oligo-metastatic disease. In recent years positron emission tomography (PET) in combination with computerized tomography (CT) and Prostate Specific Membrane Antigen (PSMA) tracers (PSMA-PET/CT) has emerged as an imaging modality to visualize (early) metastatic disease, but its accuracy in detecting oligo-metastatic spread is unknown, as small nodal metastases can be missed. In this study, the correlation is assessed between functional, quantitative and metabolic local tumor characteristics with PSMA-PET/CT-proven nodal involvement, to be able to predict metastatic potential from quantitative MRI parameters of the localized tumor. If the study shows potential for predicting presence of metastatic disease, future patients will benefit from improved nodal staging, potentially leading to more accurate and personalized treatment of the correct disease stage.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Carlijn Tenbergen
- Telefonnummer: +31 24 36 52285
- E-Mail: carlijn.tenbergen@radboudumc.nl
Studieren Sie die Kontaktsicherung
- Name: Tom Scheenen, Prof. Dr.
- Telefonnummer: +31 24 36 13157
- E-Mail: tom.scheenen@radboudumc.nl
Studienorte
-
-
-
Nijmegen, Niederlande
- Radboud University Medical Centre
-
Kontakt:
- Carlijn Tenbergen
- E-Mail: carlijn.tenbergen@radboudumc.nl
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients, diagnosed with prostate cancer by prostate biopsy and having a high risk of nodal metastases, will be recruited at the Radboudumc in Nijmegen. This research population will be a suitable reflection of the potential patient group who will eventually benefit from this new diagnostic mpMRI approach, in case the results match the hypothesis. Characteristics of this group will comprise all men with an expected age in the range of 50-75 years.
Patients will be informed about the ongoing study by their treating physician. Patients will receive the patient information folder and will be contacted by one of the researchers. Upon approval, informed consent paperwork will be handed.
Beschreibung
Inclusion Criteria:
- Histologically proven primary cancer of the prostate, based on prostate biopsy-core analysis.
- Patient is scheduled and fit for PSMA-PET/CT
- Age≥50 years. Ability to give voluntary written informed consent to participate in this study.
Exclusion Criteria:
- Contraindication for MRI-scanning, i.e. claustrophobia, intracranial metal clips, metallic bodies in the eye, implanted electric and electronic devices not eligible for MRI (pacemakers, insulin pumps, cochlear implants, neurostimulators).
- Prior prostate cancer treatment.
- Prior pelvic surgery, associated with pelvic lymphadenopathy
- Presence of any medical condition that in the opinion of the investigator/treating physician will affect patients' clinical status by participating in this trial.
- Inability to lie still for 45 minutes or comply with imaging.
- The patient is already enrolled in one or more concurrent studies, which could confound the results of this study, according to the investigators.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Nur Fall
- Zeitperspektiven: Interessent
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
optimal combination of quantitative MRI parameters that best correlates to the presence of (lymph node) metastases in prostate cancer as seen on PSMA-PET/CT.
Zeitfenster: within 14 days of PSMA-PET/CT scan, before any therapy
|
To find the optimal combination of quantitative parameters for discriminating between positive and negative PSMA-PET/CT, logistic regression modelling will be used.
The performance of the model will be evaluated using receiver operating characteristic curve analysis.
|
within 14 days of PSMA-PET/CT scan, before any therapy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
the performance of individual quantitative MRI parameters discriminating localized from (oligo-)metastatic disease
Zeitfenster: within 14 days of PSMA-PET/CT scan, before any therapy
|
To test the individual quantitative MRI parameters for a significant difference between localized and (oligo-)metastatic disease, non-parametric tests for independent groups (Mann-Whitney U test) will be used.
The ability of each parameter to discriminate between positive and negative PSMA-PET/CT is assessed using receiver operating characteristic curve analysis, which allows comparison to the logistic regression model performance.
|
within 14 days of PSMA-PET/CT scan, before any therapy
|
MR parameters that correlate to the amount of metastases as found on PSMA-PET/CT
Zeitfenster: within 14 days of PSMA-PET/CT scan, before any therapy
|
Participants with a positive PET/CT scan result will be divided in groups according to the number of positive lymph nodes detected (if variance within participants allows).
To test for significant differences between these groups for each of the quantitative parameters, the non-parametric tests for multiple independent groups (Kruskal Wallis) will be used.
|
within 14 days of PSMA-PET/CT scan, before any therapy
|
MR parameters that correlate to local prostate PSMA-PET intensity
Zeitfenster: within 14 days of PSMA-PET/CT scan, before any therapy
|
To test for a correlation between the quantitative parameters and the local prostate PSMA-PET intensity, a spearmans rho test for correlation between two continuous variables will be used.
|
within 14 days of PSMA-PET/CT scan, before any therapy
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Tom Scheenen, Radboud university medical center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NL77789.091.21
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur MRI examination of the prostate
-
Memorial Sloan Kettering Cancer CenterBeendetDie Familien oder nächsten Angehörigen von Patienten, die am MSKCC wegen nichtkutaner Plattenepithelkarzinome behandelt wurden | Oberer AerodigestivtraktVereinigte Staaten
-
Skin Analytics LimitedAbgeschlossenBasalzellkarzinom | Plattenepithelkarzinom | Malignes Hautmelanom T0Vereinigte Staaten, Italien
-
Skin Analytics LimitedInnovate UKAbgeschlossen
-
Skin Analytics LimitedInnovate UKAbgeschlossen
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnbekanntHändewaschenNiederlande
-
Buddhist Tzu Chi General HospitalAbgeschlossen
-
Duke UniversityNational Institute of Mental Health (NIMH); National Institute for Medical Research... und andere MitarbeiterRekrutierungAdhärenz, Medikamente | HIV-1-Infektion | Problem der psychischen GesundheitTansania
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...RekrutierungCOVID-19 | Magen-Darm-BlutungenKanada
-
Buddhist Tzu Chi General HospitalRekrutierung
-
University of SurreyNoch keine RekrutierungWellness, PsychologieVereinigtes Königreich